BioPharma Drive: Drug Pricing

DECEMBER 12, 2023

Just before clearing Pfizer’s buyout of Seagen, the regulator threatened to block Sanofi’s licensing deal with Maze Therapeutics, a challenge the biotech called ‘‘unprecedented.”

Drug Research 304

Drug Research Licensing Licensing Research 304

Conversations in Drug Development Trends

FEBRUARY 21, 2024

The on-site cGMP Phase 1 pharmacy must have radiolabel drug preparation experience A clinical pharmacology unit (CPU) must be licensed and experienced in handling radioactive investigational drugs in order to complete your AME study.

Clinical Trials 80

Clinical Trials Pharmacy Clinical Pharmacology FDA 80

DrugBank

MARCH 22, 2024

These data sources are known for being highly referenced and usable for specific research activities; further yet, a number of recognizable open sources, along with their identifiers, are considered industry standard resources. Paid Knowledge Bases Paying for access or licensing a knowledge base can be a difficult decision to make.

Licensing 73

Licensing Licensing Research Clinical Trials 73

Codon

JANUARY 21, 2024

We wouldn't do a challenge trial for Ebola, because the disease is extremely severe, and there are currently no licensed treatments or vaccines. There have been deaths in phase 1 medical and drug research among healthy participants. You can do a challenge trial with deadly diseases, but you need a “rescue therapy.”

Vaccine 118

Vaccine Trials Disease Treatment 118

The Pharma Data

JANUARY 26, 2021

Lilly licensed etesevimab from Junshi Biosciences after it was jointly developed by Junshi Biosciences and Institute of Microbiology, Chinese Academy of Science (IMCAS). However, as with any such undertaking, there are substantial risks and uncertainties in the process of drug research, development and commercialization.

Hospitals 52

Hospitals Treatment Trials Long-Term Care Facilities 52

Drug Target Review

FEBRUARY 11, 2025

New era in drug research: data access and NGS The 1990s and 2000s marked a turning point in the drug development landscape, facilitated by a combination of cultural and technological factors that enabled regulatory changes, technological innovations and methodological advances.

Drug Development 59

Drug Development Bioinformatics Drugs Small Molecule 59